Klinische forschung in der psychopharmakologie - III. Erreichte qualität der psychopharmakotherapie und bedarf an innovation: Antidepressive substanzen

Psychopharmakotherapie

Volumn 3, Issue 2, 1996, Pages 77-80

  Aldenhoff, Josef ^a   Fritze, Jürgen ^a,b  

^a Klin F Psychiat Psychotherapie 1 ^*

^b Zentrum der Psychiatrie   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; CHLORPROMAZINE; CLOMIPRAMINE; FLUOXETINE; FLUSPIRILENE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; LIOTHYRONINE; LITHIUM SALT; MAPROTILINE; MIANSERIN; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; PAROXETINE; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; TRANYLCYPROMINE; TRAZODONE;

BEHAVIOR THERAPY; DEPRESSION; HUMAN; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; RESEARCH; SHORT SURVEY;

EID: 0029886787     PISSN: 09446877     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (42)

1. Abel JL. Exposure with response prevention and serotonergic antidepressants in the treatment of obsessive-compulsive disorder: A review and implications for interdisciplinary treatment. Behav Res Ther 1993;31:463-78.
2. Angermeyer MC. Das Bild der Psychiatrie in der Öffentlichkeit. In: Reimer F, Hrsg. Versorgungsstrukturen in der Psychiatrie. Berlin: Springer-Verlag, 1994:1-10.
3. Beck AT. Cognitive Therapy: Past, Present and Future. J Consult Clin Psychol 1993;61:194-8.
4. Brogden RN,Heel RC,SpeightTM,Avery GS. Mianserin: a review of its pharmacological properties and therapeutic efficacy in depressive illness. Drugs 1978;16:273-301.
5. Callahan AM, Fava M, Rosenbaum JF. Drug interactions in psychopharmacology. Psychiatr Clin North Am 1993;16:647-71.
6. Cesura AM, Pletcher A. The new generation of monoamine oxidase inhibitors. Prog Drug Res 1992;38:171-97.
7. Danish University Antidepressant Group. Moclobemide: a reversible MAO-A inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study. J Affect Disord 1993;28:105-16.
8. Dalgalarrondo P, Gattaz WF. Basal ganglia abnormalities in tardive dyskinesia. Possible relationship with duration of neuroleptic treatment. Eur Arch Psychiatry Clin Neurosci 1994; 244:272-7.
9. Den Boer JA, Westenberg HGM. Effect of serotonin and noradrenalin uptake inhibitors in panic disorder: a double-blind comparative study with fluvoxamine and maprotiline. Int . Clin Psychopharmacol 1988;3:59-74.
10. Diekstra RFW. The epidemiology of suicide and parasuicide. Acta Psychiatr Scand 1993; 371(Suppl):9-20.
11. Fritze J, Decket J, Lanczik M, Strik W, et al. Zum Stand der Aminhypothesen depressiver Erkrankungen. Nervenarzt 1992;63:3-13.
12. Fritze J. The Adrenergic-Cholinergic Imbalance Hypothesis of Depression: A Review and a Perspective. Rev Neurosci 1993;4:63-93.
13. Fritze J. Unerwünschte Begleitwirkungen der Antidepressiva und ihre Behandlung. In: Möller HJ, Hrsg. Therapie psychiatrischer Erkrankungen. Stuttgart: Enke, 1993:287-301.
14. Fritze J. Klinische Forschung in der Psychopharmakologie: I. Gesundheitskosten, Strukturänderung, Folgen für die pharmakologische Forschung. Psychopharmakotherapie 1994; 1: 57-9.
15. Fritze J, Aldenhoff J. Klinische Forschung in der Psychopharmakologie: II. Erreichte Qualität der Psychopharmakotherapie und Bedarf an Innovation: Antipsychotische und nootrope Substanzen. Psychopharmakotherapie 1994; 1:117-21.
16. Greden JF. Antidepressant maintenance medications: when to discontinue and how to stop. J Clin Psychiatry 1993;54:39-45.
17. Hand I. Verhaltenstherapie und/oder Pharmakotherapie bei Depressionen? Fortschr Neurol Psychiatr 1994;62:Sonderheft 1:44-52.
18. Henry JA. Debits and credits in the management of depression. BrJ Psychiatry 1993;163 (Suppl 20):33-9.
19. Hiemke C. Therapeutisches Drug monitoring von Antidepressiva und Neuroleptika. Psychopharmakotherapie 1995:2:21-3.
20. Hirschfeld MA. Guidelines for the long-term treatment of depression. J Clin Psychiatry 1994;55:12(Suppl):61-9.
21. Sacsson G, Holmgren P, Wasserman D, Bergman U. Use of antidepressants among people committing suicide in Sweden. Br Med J 1994;308:506-9.
22. Joffe RT,Levitt RJ,Bagby RM,MacDonald C, et al. Predictors of response to lithium and triiodothyronine augmentation of antidepressants in tricyclic non-responders. Br J Psychiatry 1993;163:574-8.
23. Kapur S, Mieczkowski T, Mann J. Antidepressant medications and the relative risk of suicide attempt and suicide. J Am Med Assoc 1992;268:3441-5.
24. Kasper S, Fuger J, Möller HJ. Comparative efficacy of antidepressants. Drugs 1992;43 (Suppl 2):11-23.
25. Kasper S, Möller HJ. Antidepressive Psychopharmakotherapie. Dtsch Ärztebl 1995;92: B318-22.
26. Kleine TO, Naumann-Haak C, Hackler R, Hess M, et al. Bestimmung von trizyklischen Antidepressiva im Blutserum. Psychopharmakotherapie 1995;2:27-8.
27. Klerman GL, Weissmann MM, Rouseville BJ, Chevron ES. Interpersonal Psychotherapy of Depression. New York: Basic Books, 1984.
28. Leonard BE, Stokes PE, Greden JF, Pande AC, et al. The comparative pharmacology of new antidepressants. J Clin Psychiatry 1993;54 (Suppl):3-15.
29. Melander A, Henricson K, Stenberg P,Lowenhielm P, et al. Anxiolytic-hypnotic drugs: Relationship between prescribing, abuse and suicide. Eur J Clin Pharmacol 1991;41:525-9.
30. Mitchell JE, Raymond M, Specker S. A review of the controlled trials of pharmacotherapy and psychotherapy in the treatment of bulimia nervosa. Int J Eat Disord 1993; 14:229-47.
31. Möller HJ. Antidepressants do they decrease or increase suicidality? Pharmacopsychiatry 1992;25:249-53.
32. Parker G, Roy K, Hadzi-Pavlovic D, Pedic F. Psychotic (delusional) depression: A metaanalysis of physical treatments. J Affect Disord 1992;24:17-24.
33. Preskom SH. Pharmacokinetics of antidepressants: Why and how they are relevant to treatment. J Clin Psychiatry 1993;54(Suppl):14-34.
34. Prien RF, Kupfer DJ. Continuation drug therapy for major depressive episodes: How long should it be maintained? Am J Psychiatry 1986;143:18-23.
35. Rickels K, Downing R,Schweizer E,Hassman H. Antidepressants for the treatment of generalized anxiety disorder: A placebo-controlled comparison of imipramine, trazodone and diazepam. Arch Gen Psychiatry 1993;50:884-95.
36. Rosenberg R. Drug treatment of panic disorder. Pharmacol Toxicol 1993;72:344-53.
37. Schmidtke A, Häfner H. Suizide und Suizidversuche. Epidemiologie in der Bundesrepublik Deutschland. Münch Med Wochenschr 1985;127:828-32.
38. Spigset O, Mjorndal T. Serotonin syndrome cause by a moclobemide-clomipramine interaction. Br Med J 1993;306:248.
39. Stassen HN, Delini-Stula A, Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur Neuropsychopharmacol 1993;3:127-33.
40. Stewart JW, McGrath PJ, Rabkin JG, Quitkin FM. Atypical depression: A valid clinical entity? Psychiatr Clin North Am 1993;16:479-95.
41. Taiminen TJ. Effect of psychopharmacotherapy on suicide risk in psychiatric inpatients. Acta Psychiatr Scand 1993;87:45-7.
42. Wenzel P Johanniskraut - Was bringt die Zukunft. TW Neurol Psychiatr 1993;7:618.